|Bid||29.00 x 800|
|Ask||33.91 x 1000|
|Day's Range||31.69 - 33.25|
|52 Week Range||23.55 - 52.22|
|Beta (5Y Monthly)||1.31|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 09, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ:ANIP) today announced that it has acquired the new drug applications ("NDAs") for OXISTAT® Lotion, VEREGEN® Ointment, and Pandel® Cream and the abbreviated new drug application ("ANDA") for ApexiCon® E Cream from Sandoz Inc. Pandel® Cream will be transitioned later upon receiving the requisite approvals. Collectively, these products generated net revenues of $13.2 million in 2020. The acquisition was funded through borrowings under the Company’s pre-existing revolver credit facility.
ANI Pharmaceuticals (ANIP) has moved higher as of late, but there could definitely be trouble on the horizon for this company
It's now my pleasure to turn the floor over to Ms. Lisa Wilson, Investor Relations for ANI Pharmaceuticals. This is Lisa Wilson of In-Site Communications, Investor Relations for ANI. With me on today's call are Nikhil Lalwani, President and Chief Executive Officer and Steve Carey, Chief Financial Officer of ANI.